Monday, August 25, 2025

Latest

DiagnaMed Enhances CERVAI Brain Health Platform Commercialization Efforts In Canada

FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.

DiagnaMed Holdings (CSE: DMED) continues to progress with the commercialization of its CERVAI Brain Health AI Platform. The platform has recently been accepted into the Hamilton Ecosystem to Accelerate and Leverage Trials of Health Innovation, which is also known as the HEALTHI program.

The HEALTHI program has been designed to assist in developing relationships with clinicians and hospital facilities ahead of conducting clinical trials or commercialization efforts in Canada. Developed in partnership with the National Research Council of Canada, the program connects two research hospitals, Hamilton Health Sciences and The Research Institute at St. joe’s Hamilton, with businesses that are entering the commercialization stage.

“We are pleased to be accepted into the HEALTHI program to accelerate our commercialization initiatives of CERVAI™, a novel brain health AI platform, and validate its potential in improving overall brain health. As part of our commercialization plans, we continue leveraging expertise from Canada’s respected life sciences ecosystem to improve CERVAI™’s positioning and global expansion goals,” commented DiagnaMed CEO Fabio Chianelli.

Acceptance into the HEALTHI program is expected to accelerate clinical research as well as commercialization efforts of the CERVAI platform in Canada.

READ: DiagnaMed Begins Test Launch of CERVAI

CERVAI has been developed to assess risk levels for the development of Alzheimer’s and other neurological issues through the use of a series of tests. These tests produce three results, referred to as a Resilience Index, a Vulnerability Index, and a Number-Symbol Coding Task. When brought together, these results assist in assessing a patients risk for developing neurological issues by providing a snapshot of brain health.

A test pilot program is underway across Canada and the US, which is available at 25 clinics currently.

DiagnaMed Holdings last traded at $0.05 on the CSE.


FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

First Majestic Q2 Earnings: Another Record Quarter

Sandstorm Gold Fades Into Royal Gold Merger

Equinox Gold Q2 Earnings: Back On Track

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

DiagnaMed Opens Enrollment For Healthcare Provider Network For Brain Health Platform

DiagnaMed Holdings (CSE: DMED) is moving forward with the commercialization of CERVAI, its brain health...
Tuesday, October 3, 2023, 09:08:43 AM

DiagnaMed Begins Test Launch of CERVAI

A test launch is currently underway for CERVAI, which has been deemed as a world-first...
Wednesday, February 28, 2024, 10:25:10 AM

DiagnaMed Unveils First Commercial AI Product For Healthcare Industry, FormGPT

DiagnaMed Holdings (CSE: DMED) has launched its first commercial product under its initiative to bring...
Wednesday, May 3, 2023, 08:28:00 AM

DiagnaMed Expects Brain Health AI Platform To Be Commercialized In Q4 2023

DiagnaMed Holdings (CSE: DMED) is anticipating to begin the commercialization stage of its flagship CERVAI...
Wednesday, September 13, 2023, 09:58:53 AM

DiagnaMed Licenses Brain Health Tech From University Of Miami For AI Platform

DiagnaMed Holdings (CSE: DMED) is moving to enhance its brain health artificial intelligence platform known...

Wednesday, February 22, 2023, 09:03:30 AM